

Pre-Exposure Prophylaxis 101 Providers have the Power

What is PrEP?

Protection for a person who is HIV negative who is at high risk of HIV exposure through sex or injection drug use



What is PrEP?

PrEP can reduce risk of acquiring HIV by more than:


90% for sexual exposure

70% for injection drug use

Pills must be taken <u>every day</u> as prescribed for this level of effectiveness



What PrEP is Not



PrEP does not:

- Reduce the need for other HIV prevention options
- Protect against other STIs

Available Medications for PrEP

Daily oral PrEP is recommended for:

• All adults/adolescents at risk for HIV through sex or IDU





Available Medications for PrEP

- Tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC) has been used since 2012
- One pill once a day
 - >> On-demand use is an option






Higher TFV-DP Levels in PBMCs with TAF vs TDF

Tenofovir Alafenamide (TAF)

- Pro-drug that can be absorbed quicker than TDF
- Can be prescribed in smaller doses, as higher levels of the active drug, tenofovir diphosphate, is seen in the cells



Higher TFV-DP Levels in PBMCs with TAF vs TDF



Ruane. JAIDS. 2013;63:449. Sax. JAIDS. 2014;67:52. Sax. Lancet. 2015;385:2606.

Indications for PrEP

	MSM		Heterosexual Men/Women		People Who Inject Drugs
•	Any male sex partner in past 6 mos.	•	Any sex with opposite sex partner in past 6 mos.	•	Any injection of drugs not prescribed by a clinician in past 6 mos.
•	Not in a monogamous relationship with a recently tested, HIV negative man	•	Not in a monogamous relationship with a recently tested, HIV negative partner	•	Any sharing of injection/drug preparation equipment in past 6 mos.
•	Any anal sex without a condom in the past 6 mos.	•	Infrequent condom use with >1	•	Risk of sexual acquisition
•	Bacterial STI (syphilis, gonorrhea, or chlamydia) in past 6 mos.		partners(s) with unknown HIV status at substantial risk of HIV infection (PWID or MSM)		
		•	ls in an ongoing relationship with HIV- positive partner with unsupressed HIV-1 RNA		
		•	Bacterial STI (syphilis, gonorrhea in females/males) in past 6 mos		

For adults or adolescents weighing >35kg without acute or established HIV infection only

Contraindications to TDF/FTC for PreP

Active HIV Infection	Need HAART: 3-active medications
Renal Dysfunction	TDF: Do not start if CrCl <60 mL/min; Stop if CrCl <50 mL/min
	TAF: If CrCl < 30 mL/min
Allergy to TDF or FTC	Long Acting Cabotegravir

Caution with active HBV infection as discontinuation of TDF/FTC can lead to hepatitis flair


FTC/TDF: emtricitabine/tenofovir disoproxil fumarate; TAF: tenofovir alafenamide

https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf

Once Daily Oral TDF-Based PrEP Efficacy in Clinical Trials

Population	Study	Study Drug	Control	Efficacy for Reducing HIV Incidence, %
MSM	iPrEx ¹	FTC/TDF (n = 1251)	Placebo (n = 1248)	44.0 (<i>P</i> = .005)
HS men &	Partners PrEP ²	FTC/TDF (n = 1583)	Placebo (n = 1586)	75.0 (<i>P</i> <.001)
women	TDF2 ³	FTC/TDF (n = 611)	Placebo (n = 608)	62.2 (<i>P</i> = .03)
PWID	BTS ⁴	TDF (n = 1204)	Placebo (n = 1207)	48.9 (<i>P</i> = .01) If detectable TDF: 73.5 (<i>P</i> = .03)

Effectiveness Improves with Adherence



1. Marrazzo. NEJM. 2015;372:509. 2. Van Damme. NEJM. 2012;367:411. 3. Grant. NEJM. 2010;363:2587. 4. Thigpen. NEJM. 2012;367:423. 5. Baeten. NEJM. 2012;367:399. 6. McCormack. Lancet. 2016;387:53.



Summary of PrEP Eligibility

Risk Group	Daily FTC/TDF	On-Demand (2:1:1) FTC/TDF	Daily FTC/TAF
MSM	Approved, guideline recommended	<mark>Off-label</mark> , guideline recommended	Approved
TG women	Approved, guideline recommended	Off-label , <u>not</u> recommended	Approved
Heterosexual women	Approved, guideline recommended	Off-label , <u>not</u> recommended	Off-label , <u>not</u> recommended, studies underway
Heterosexual men	Approved, guideline recommended	Off-label , <u>not</u> recommended	Approved
TG men	Approved , guideline recommended	Off-label , <u>not</u> recommended	Off-label , <u>not</u> recommended (unless risk from anal sex only)
PWID FTC/TAF PI. FTC/TDF PI. Saag. JAMA. 2020;324:1651. Tan. CMA.	Approved, guideline recommended J. 2017;189:E1448. WHO. apps.who.int/iris/bitstream/handle/10665/32595!	Off-label , <u>not</u> recommended	Off-label, not recommended

Long-Acting Cabotegravir (CAB LA)

Details:

- Injectable integrase inhibitor
- Administered every 8 weeks
- FDA approved for MSM and transgender women
- Safety similar to that of TDF-FTC

Except for injection site side effects leading to discontinuation, which occurred in 2.4% of patients receiving it vs none in the placebo group during the clinical trial

IHS HIV Project ECHO

Monthly IHS telemedicine conference:

- Sponsored by University of New Mexico and IHS
- Twenty-minute didactic talk regarding HIV care
- Participants present 2-3 active cases

When?

• 2nd Wednesday of the month @ 12pm MT

IHSECHO@unm.salud.edu



HIV/AIDS Warmline



NATIONAL CLIN CONSULTATION Translating science into care	ICIAN CENTER	The National Clinician Consultation Center is a free telephone advice service for clinicians, by clinicians. Go to nccc.ucsf.edu for more information.		
HIV/AIDS Warmline 800-933-3413	HIV treatment, ARV management, complications, and co- morbidities	Perinatal HIV Hotline 888-448-8765	Pregnancy, breastfeeding and HIV	
Hepatitis C Warmline 844-HEP-INFO/ 844-437-4636	HCV testing, staging, monitoring, treatment	Substance Use Warmline 855-300-3595	Substance use evaluation and management	
PrEPline 855-HIV-PrEP	HIV Pre-exposure prophylaxis	PEPline 888-448-4911	Occupational & non- occupational exposure management	


This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U10HA30039 (AIDS Education and Training Centers National Clinician Consultation Center) in partnership with the Centers for Disease Control and Prevention awarded to the University of California, San Francisco.

Indian Country ECHO

Free service for I/T/U clinicians:

Designed to enhance care delivery for patients with complex conditions

The variety of services include: Online ECHO clinics, trainings, CE, and technical assistance & capacity building



Virtual ECHO Clinics

During ECHO clinics you can:

- Participate in didactic and case presentations
- Receive recommendations from peers and a team of specialists
- Join a learning community

Join us!



More Information & To Get Connected

IndianCountyECHO.org

For free technical assistance: ECHO@npaihb.org



